PDCD1 and cancer: These multi-facetted binding patterns in trans and cis may contribute to the fine-tuning of the immune response within the TME, and may be the cause for the differences observed when treating cancer patients with anti-PD-1 versus anti-PD-L1 blocking antibodies (Duan et al., 2019).